Atea Pharmaceuticals (AVIR) EVP awarded 108,000 options and RSU shares vest

Rhea-AI Filing Summary

Atea Pharmaceuticals EVP and Chief Accounting Officer Wayne Foster reported equity compensation and related share activity. On January 31, 2026, 33,333 and 8,000 restricted stock units (RSUs) converted into an equal number of Atea common shares as vesting and performance conditions were met.

Following these conversions (coded M), Foster held 91,461 common shares before tax withholding. A separate transaction (code F) shows 12,132 shares withheld at $4.24 per share to cover taxes, leaving 79,329 common shares held directly.

Foster also received a new stock option grant for 108,000 shares at a $4.24 exercise price. The option vests in forty‑eight equal monthly installments after January 31, 2026, becoming fully vested on January 31, 2030, with 108,000 options beneficially owned directly after the grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Wayne

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		41,333	A	(1)	91,461	D
Common Stock	01/31/2026		F		12,132	D	$4.24	79,329	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		M			33,333	(2)	(2)	Common Stock	33,333	$0	0	D
Restricted Stock Units	(1)	01/31/2026		M			8,000	(3)	(3)	Common Stock	8,000	$0	0	D
Stock Option (Right to Buy)	$4.24	01/31/2026		A		108,000		(4)	01/30/2036	Common Stock	108,000	$0	108,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

3. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

4. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Wayne Foster	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Atea Pharmaceuticals (AVIR) report for Wayne Foster?

Atea reported that EVP and Chief Accounting Officer Wayne Foster had RSUs vest into common stock, shares withheld for taxes, and a new stock option grant. These transactions reflect routine equity compensation and do not describe an open‑market stock purchase or sale.

How many Atea (AVIR) RSUs vested for Wayne Foster on January 31, 2026?

On January 31, 2026, 33,333 RSUs from a 100,000‑unit grant and 8,000 performance‑based RSUs vested for Wayne Foster. Each RSU represents a right to receive one Atea common share, so 41,333 common shares were issued to him through these vesting events.

How many Atea (AVIR) common shares does Wayne Foster hold after these Form 4 transactions?

After the January 31, 2026 transactions, Wayne Foster beneficially owned 79,329 Atea common shares directly. This figure reflects RSU conversions into stock and 12,132 shares withheld at $4.24 per share to satisfy tax obligations associated with the equity vesting.

What stock option grant did Wayne Foster receive from Atea Pharmaceuticals (AVIR)?

Wayne Foster received a stock option for 108,000 Atea common shares at a $4.24 exercise price. The option vests in forty‑eight equal monthly installments following January 31, 2026, and will be fully vested by January 31, 2030, if he continues to meet vesting conditions.

Were any of Wayne Foster’s Atea (AVIR) shares sold on the open market?

The Form 4 shows 12,132 Atea shares with transaction code F at $4.24, designated for tax withholding. This generally indicates shares withheld by the issuer to cover taxes, rather than an open‑market discretionary sale to third‑party buyers.

What do the performance RSUs in Atea (AVIR) Wayne Foster’s filing represent?

The filing notes that 8,000 RSUs reflect satisfaction of performance criteria for previously granted performance restricted stock units. These vested on January 31, 2026, converting into 8,000 Atea common shares once the specified performance conditions were achieved.